NCT05431270: Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with prior T-cell, NK cell, or CD73 inhibitor therapy; Prior checkpoint inhibitor anti PD-1 & anti PD-L1 therapies are allowed (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)

Comments are closed.

Up ↑